Bank of New York Mellon’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $904K | Buy |
28,741
+2,698
| +10% | +$74.3K | ﹤0.01% | 3429 |
|
|
2026
Q1 | $525K | Buy |
26,043
+2,950
| +13% | +$57.1K | ﹤0.01% | 3573 |
|
|
2025
Q4 | $476K | Sell |
23,093
-1,558
| -6% | -$38.8K | ﹤0.01% | 3640 |
|
|
2025
Q3 | $427K | Buy |
24,651
+889
| +4% | +$17.9K | ﹤0.01% | 3681 |
|
|
2025
Q2 | $355K | Sell |
23,762
-683
| -3% | -$10.7K | ﹤0.01% | 3712 |
|
|
2025
Q1 | $286K | Buy |
24,445
+1,844
| +8% | +$32K | ﹤0.01% | 3724 |
|
|
2024
Q4 | $517K | Sell |
22,601
-69
| -0.3% | -$2.57K | ﹤0.01% | 3504 |
|
|
2024
Q3 | $951K | Sell |
22,670
-7,758
| -25% | -$301K | ﹤0.01% | 3163 |
|
|
2024
Q2 | $1.11M | Buy |
+30,428
| New | +$1.07M | ﹤0.01% | 3137 |
|
|
2023
Q3 | – | Sell |
-719
| Closed | -$11.9K | – | 4388 |
|
|
2023
Q2 | $11.9K | Hold |
719
| – | – | ﹤0.01% | 4328 |
|
|
2023
Q1 | $10.1K | Hold |
719
| – | – | ﹤0.01% | 4359 |
|
|
2022
Q4 | $7.32K | Hold |
719
| – | – | ﹤0.01% | 4437 |
|
|
2022
Q3 | $9K | Sell |
719
-4
| -0.6% | -$82 | ﹤0.01% | 4512 |
|
|
2022
Q2 | $15K | Sell |
723
-5,078
| -88% | -$124K | ﹤0.01% | 4520 |
|
|
2022
Q1 | $218K | Sell |
5,801
-107
| -2% | -$6.24K | ﹤0.01% | 4191 |
|
|
2021
Q4 | $570K | Sell |
5,908
-230
| -4% | -$28K | ﹤0.01% | 3718 |
|
|
2021
Q3 | $887K | Buy |
6,138
+381
| +7% | +$58.3K | ﹤0.01% | 3457 |
|
|
2021
Q2 | $1.06M | Sell |
5,757
-30
| -0.5% | -$6.64K | ﹤0.01% | 3374 |
|
|
2021
Q1 | $1.43M | Sell |
5,787
-177
| -3% | -$45.2K | ﹤0.01% | 3126 |
|
|
2020
Q4 | $1.68M | Buy |
5,964
+397
| +7% | +$97K | ﹤0.01% | 2946 |
|
|
2020
Q3 | $1.34M | Sell |
5,567
-308
| -5% | -$74.6K | ﹤0.01% | 2937 |
|
|
2020
Q2 | $1.95M | Buy |
5,875
+4,736
| +416% | +$1.23M | ﹤0.01% | 2701 |
|
|
2020
Q1 | $259K | Buy |
1,139
+346
| +44% | +$71.2K | ﹤0.01% | 3664 |
|
|
2019
Q4 | $195K | Sell |
793
-31
| -4% | -$3.09K | ﹤0.01% | 3922 |
|
|
2019
Q3 | $47K | Hold |
824
| – | – | ﹤0.01% | 4128 |
|
|
2019
Q2 | $39K | Hold |
824
| – | – | ﹤0.01% | 4143 |
|
|
2019
Q1 | $44K | Sell |
824
-24
| -3% | -$1.21K | ﹤0.01% | 4106 |
|
|
2018
Q4 | $37K | Hold |
848
| – | – | ﹤0.01% | 4095 |
|
|
2018
Q3 | $50K | Hold |
848
| – | – | ﹤0.01% | 4124 |
|
|
2018
Q2 | $45K | Sell |
848
-221
| -21% | -$57.6K | ﹤0.01% | 4108 |
|
|
2018
Q1 | $301K | Buy |
1,069
+221
| +26% | +$61K | ﹤0.01% | 3797 |
|
|
2017
Q4 | $200K | Sell |
848
-315
| -27% | -$73.8K | ﹤0.01% | 3952 |
|
|
2017
Q3 | $330K | Hold |
1,163
| – | – | ﹤0.01% | 3728 |
|
|
2017
Q2 | $327K | Buy |
1,163
+165
| +17% | +$47.2K | ﹤0.01% | 3783 |
|
|
2017
Q1 | $333K | Sell |
998
-5
| -0.5% | -$1.76K | ﹤0.01% | 3716 |
|
|
2016
Q4 | $331K | Buy |
1,003
+165
| +20% | +$44.4K | ﹤0.01% | 3750 |
|
|
2016
Q3 | $224K | Sell |
838
-31
| -4% | -$6.25K | ﹤0.01% | 3862 |
|
|
2016
Q2 | $115K | Sell |
869
-493
| -36% | -$78.4K | ﹤0.01% | 4026 |
|
|
2016
Q1 | $240K | Buy |
1,362
+493
| +57% | +$95.8K | ﹤0.01% | 3721 |
|
|
2015
Q4 | $217K | Hold |
869
| – | – | ﹤0.01% | 3842 |
|
|
2015
Q3 | $244K | Buy |
+869
| New | +$200K | ﹤0.01% | 3838 |
|
Other funds holding NGNE
RBI
N
Bank of New York Mellon's NGNE Position: Q2 2026 in Review
Bank of New York Mellon increased its Neurogene (NGNE) stake by 10% in Q2 2026, buying an estimated $74.3K and bringing the position to 28,741 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #3429.
Bank of New York Mellon first reported a position in NGNE in Q3 2015 and has held it in 41 quarters since. The position peaked at $1.95M in Q2 2020. 49 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.
- Bank of New York Mellon held 28,741 shares of Neurogene worth $904K as of Q2 2026.
- Bank of New York Mellon bought 2,698 Neurogene shares in Q2 2026, an estimated $74.3K.
- Neurogene made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3429 holding.
- Bank of New York Mellon first reported a position in Neurogene in Q3 2015 and has held it in 41 quarters since.
- Bank of New York Mellon's Neurogene position peaked at $1.95M in Q2 2020.
- 49 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.